Valeant Pharmaceuticals warned on Tuesday it faces a default risk if it fails to file a key report by April 29. The drug maker also said the cancellation of its controversial price hikes is hurting its business.
Valeant stock collapses 50%
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться